Margarett Ellison, MD
Gynecologic Oncology · Moultrie, GANPI 1871591297
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Intuitive Surgical at 53.8% of the total.
Across 270 payments — averaging $301.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$44K
- Merck$14K
- AstraZeneca$11K
- Myriad Genetic Laboratories, Inc.$6K
- Eisai Inc.$2K
- GSK$1K
- plus $3K from 34 others
Across 4 payments — averaging $36,106 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$144K
What the payments were for
- Consulting fees$1,6202%
- Speaking & faculty fees$27,84034%
- Travel & lodging$9,38012%
- Food & beverage$7,2169%
- Education$35,22543%
- Gifts$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 69 | $43,823 |
| Merck | 35 | $13,815 |
| AstraZeneca(2 entities) | 15 | $10,664 |
| Myriad Genetic Laboratories, Inc. | 21 | $6,431 |
| Eisai Inc. | 14 | $1,889 |
| GSK | 9 | $1,422 |
| Vertex | 4 | $784 |
| Astellas Pharma US Inc | 16 | $270 |
| AbbVie | 8 | $244 |
| Seagen Inc. | 9 | $236 |
| Tesaro, Inc. | 2 | $224 |
| Johnson & Johnson(3 entities) | 6 | $202 |
| Daiichi Sankyo Inc. | 8 | $189 |
| Clovis Oncology, Inc. | 3 | $126 |
| Mallinckrodt Enterprises LLC | 1 | $125 |
| Amgen | 8 | $122 |
| Regeneron Healthcare Solutions, Inc. | 5 | $113 |
| Caris MPI, Inc. | 1 | $109 |
| Jazz Pharmaceuticals Inc. | 4 | $106 |
| Pharmacosmos Therapeutics Inc. | 4 | $70 |
| Incyte Corporation | 4 | $65 |
| Boston Scientific | 3 | $57 |
| Pfizer | 2 | $41 |
| Emmaus Medical, Inc. | 2 | $33 |
| Stemline Therapeutics Inc. | 1 | $33 |
| Blueprint Medicines Corporation | 2 | $29 |
| UCB, Inc. | 1 | $25 |
| Novartis | 1 | $23 |
| Sanofi | 1 | $23 |
| Foundation Medicine, Inc. | 1 | $21 |
| Morphosys, US Inc. | 1 | $21 |
| LSI Solutions Inc | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Biom'up France SAS | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Heron Therapeutics, Inc. | 1 | $13 |
| Dova Pharmaceuticals | 1 | $13 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$42,784
- LYNPARZA$17,722
- KEYTRUDA$6,046
- PreciseTumor$4,158
- myChoice CDx$1,900
- LENVIMA$1,620
- ZEJULA$1,504
- JOURNAVX$730
- OFIRMEV$125
- CERTUS 140 MICROWAVE ABLATION SYSTEM$124
- Elahere$117
- myRisk$110
- MI CANCER SEEK$109
How this compares
$81,473 in reported general payments places this provider in the 85th percentile of 49 gynecologic oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 11 | $172,990 |
| Dextroamphetamine Sulfate | 14 | $2,158 |
| Dexamethasone | 46 | $963 |
| Prochlorperazine Maleate | 49 | $776 |
| Ondansetron OdtOndansetron | 54 | $740 |
| Ibuprofen | 106 | $434 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 80 | $343 |
| Imiquimod | 12 | $326 |
| Anastrozole | 21 | $319 |
| Metronidazole | 18 | $282 |
| Cephalexin | 29 | $258 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 17 | $246 |
| Olanzapine | 61 | $228 |
| Gabapentin | 11 | $194 |
| Ciprofloxacin Hcl | 11 | $94 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $10,664 | $172,99011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 49 gynecologic oncology providers in Georgia.
Other gynecologic oncology in Moultrie
- James BurkeSavannah$276K
- Benedict BenignoAtlanta$273K
- Sharad GhamandeAugusta$214K
- Ruchi GargNewnan$125K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Vijaya GalicGainesville$35K
- Guilherme CantuariaAtlanta$13K
- Mitzie-Ann DavisFayetteville$12K
- Cyril SpannAtlanta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.